Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Soleno Therapeutics (SLNO)

Tipranks - Tipranks - Thu Apr 9, 5:22AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Gilead Sciences (GILD) and Soleno Therapeutics (SLNO).

Easter Sale - 70% Off TipRanks

Gilead Sciences (GILD)

In a report released yesterday, Michael Yee from UBS maintained a Buy rating on Gilead Sciences, with a price target of $175.00. The company’s shares closed last Tuesday at $138.80.

According to TipRanks.com, Yee is a 1-star analyst with an average return of -0.6% and a 42.2% success rate. Yee covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, MBX Biosciences, Inc., and ALX Oncology Holdings. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Gilead Sciences with a $158.05 average price target, representing a 13.7% upside. In a report issued on March 24, Scotiabank also maintained a Buy rating on the stock with a $177.00 price target.

See today’s best-performing stocks on TipRanks >>

Soleno Therapeutics (SLNO)

Soleno Therapeutics received a Hold rating and a $53.00 price target from H.C. Wainwright analyst Ram Selvaraju today. The company’s shares closed last Tuesday at $52.35.

According to TipRanks.com, Selvaraju is a 5-star analyst with an average return of 20.7% and a 52.1% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Santhera Pharmaceuticals Holding, MoonLake Immunotherapeutics, and Aardvark Therapeutics, Inc. ;'>

The word on The Street in general, suggests a Hold analyst consensus rating for Soleno Therapeutics with a $71.20 average price target, a 36.2% upside from current levels. In a report issued on April 6, Cantor Fitzgerald also downgraded the stock to Hold with a $53.00 price target.

Read More on GILD:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).